Solutions
Advisory Services
Clinical Development
- Generics Development
- Clinical Operations
- Clinical Data Sciences
- Medical and Safety Services
- RWD & RWE Services
Post Marketing
- Safety Services
- Post marketing Studies
- Regulatory Affairs
R Programming in the Age of AI: A Pharmaverse Webinar
The conversation around R programming has fundamentally changed. What was once viewed as a niche statistical language, largely confined to academia, has steadily grown into a strategic capability for data-driven organizations, particularly in high-stakes, data-intensive industries such as clinical research, pharmaceuticals and biotech.
Yet, despite its growing relevance, many organizations remain caught between recognition and execution. They understand the value of open source data analytics tools, acknowledge the shift toward reproducibility and transparency, and are increasingly aware of AI-driven workflows. However, translating this awareness into scalable, operational change continues to be a challenge.
This gap reflects a broader industry pattern: the challenge is no longer identifying the right tools, but embedding them into real-world workflows.
What if the future of clinical programming is not about replacing legacy systems, but rethinking how they work altogether?
That shift is already underway, accelerated by the convergence of R as a programming language, open source data governance tools and AI-enabled analytics. But for many teams, the starting point remains unclear.
This is precisely where structured, example-led learning becomes critical.
The upcoming pharmaverse webinar is designed to bridge this gap, helping teams move from conceptual understanding to practical application.
The potential: A structural shift toward open, reproducible analytics
Clinical development is undergoing a fundamental transformation.
Three forces are converging:
- Rising data complexity, driven by real-world evidence, decentralized trials and multi-endpoint studies
- Increasing regulatory emphasis on transparency, traceability and reproducibility
- The integration of AI and advanced analytics into decision-making workflows
Traditional, closed systems, while reliable, are increasingly constrained in this environment. They often require significant manual intervention, lack flexibility and create barriers to scalability.
In contrast, R as a programming language has emerged as a compelling alternative: open, extensible and purpose-built for statistical computing.
As industry perspectives highlight, organizations are under pressure to deliver faster insights while maintaining rigor. Open-source ecosystems like R are uniquely positioned to meet this need, offering flexibility, scalability and cost efficiency without compromising analytical depth.
Where R programming is creating measurable value
The growing relevance of R programming is is grounded in its application across the clinical trial lifecycle.
From study design to reporting, R supports:
- Simulation and statistical planning
- Data cleaning and transformation at scale
- Advanced efficacy and safety analysis
- PK/PD modeling and visualization
- Generation of tables, listings, and figures (TLFs)
These capabilities are are interconnected, enabling end-to-end workflows that improve both efficiency and reproducibility.
At the same time, features such as interactive dashboards and dynamic reporting frameworks are enabling real-time insight generation, reducing the lag between data collection and decision-making.
One-on-One with Jeff Dickinson
Jeff Dickinson
Associate Director
Clinical Reporting
Navitas Life Sciences
We asked Jeff a few questions about R programming and here are his responses.
For professionals new to R, what practical approaches would you recommend to help them get started with confidence and avoid early-stage complexity?
Start with the pharmaverse examples page rather than a blank script, seeing complete, working ADaM code in context is far less intimidating than learning R syntax in the abstract. Tools like {admiral} map closely to concepts SAS programmers already know, so the learning curve is gentler than expected. Pair that with a low-stakes internal project and confidence builds quickly.
What are the most common challenges organizations face when transitioning from SAS to R-based workflows and how can these be effectively addressed?
The biggest hurdles are cultural, not technical , getting experienced SAS programmers to trust a new paradigm and leadership to accept open-source in a validated environment. Trying to replicate legacy SAS macros one-for-one in R is a trap; the better approach is to reframe around CDISC standards and let pharmaverse packages do the heavy lifting.
What are the potential risks for organizations that delay or avoid exploring open-source platforms?
The talent pipeline is shifting, new programmers entering the industry are increasingly R-native, and SAS-only organizations will find recruitment harder over time. There's also a competitive risk, as sponsors and partners increasingly expect R-fluent vendors who can integrate with modern workflows. Delay means a steeper catch-up curve when the pressure to transition is far greater.
How would you define pharmaverse in the context of modern clinical programming and what role does it play in advancing standardized, reproducible workflows?
Pharmaverse is a curated collection of R packages purpose-built for clinical reporting, covering the full pipeline from raw data through SDTM, ADaM, and TLGs — with CDISC standards baked in rather than bolted on. Built by the industry for the industry, it dramatically reduces infrastructure burden and replaces every organization's private macro library with a shared, version-controlled foundation.
How is Navitas Life Sciences supporting clients in operationalizing R-based programming within real-world clinical studies and what differentiates our approach?
Navitas brings both deep CDISC expertise and active pharmaverse community involvement. We're not just users of these tools but we're contributors to them. We help clients move from curiosity to production by pairing technical implementation with validated infrastructure design, meeting them whether they're in a hybrid SAS/R environment or ready for a full R-first strategy.
Despite clear advantages, adoption of R programming training and enterprise-scale R workflows remains inconsistent. A closer look reveals a common pattern:
- Sponsors and academic institutions are moving faster, leveraging R for flexibility and innovation
- Many CROs and legacy-driven organizations are taking a more cautious, phased approach
R at the intersection of AI and analytics
One of the most significant developments is the convergence of R programming with AI.
R is increasingly being used to:
- Develop predictive models for clinical outcomes
- Enable adaptive trial designs
- Automate data processing and reporting pipelines
- Support real-world evidence generation
By combining open source data governance tools with AI-enabled workflows, organizations can move toward with faster insights and more scalable analytics.
Brochure
Supercharge your clinical trials with Open-Source tools
Do you have the tools to unlock the full potential of your clinical research?
Open-Source data analytics tools are transforming clinical research by offering cost-effective, flexible, and scalable solutions for analyzing data.
As the healthcare sector increasingly integrates AI into clinical trials, these tools are crucial for keeping up with industry demands.
Download our brochure and learn more about Navitas Life Sciences’ expertise to guide your Open-Source journey in clinical research.
The practical path: Moving from exploration to execution
For many organizations, the question is no longer why R but how to start.
- Start with real workflows, not abstract training
Learning is more effective when anchored in actual use cases rather than isolated syntax. - Adopt a hybrid approach
Integrating R alongside existing systems allows organizations to build confidence without disruption. - Invest in capability building
Structured R programming online training and internal upskilling are critical to scaling adoption. - Focus on reproducibility and standards
Aligning workflows with CDISC and regulatory expectations ensures long-term sustainability.
From insight to action: Bridging the gap with pharmaverse
This is where many organizations need support not in understanding the value of R, but in translating it into practice.
The pharmaverse webinar “Pharmaverse by Example | An Introductory Webinar for Clinical Programmers” is designed to address exactly this gap.
Rather than focusing on theory, it provides:
- A guided walkthrough of real clinical workflows
- A clear view of how R packages work together across the pipeline
- Practical insights into moving from experimentation to implementation
Why this matters now
In a landscape defined by complexity, speed and increasing expectations, organizations cannot rely solely on legacy approaches. They need tools that are:
- Flexible enough to adapt
- Transparent enough to meet regulatory demands
- • Scalable enough to support future growth
R and the broader open-source tools offer that foundation.
Turning potential into capability
For teams looking to take the next step, the upcoming webinar offers a practical entry point.
Pharmaverse by Example | May 07, 2026 | 10:00 – 11:00 EST
Designed for:
- Clinical programmers and statisticians
- Teams exploring R programming training
- Leaders evaluating open source data analytics tools
This session focuses on what matters most:
how to begin, how to build confidence and how to scale.
A shift that is already underway
The transition to R as a programming language in clinical development is already happening. The organizations that will lead in this next phase are those that recognize the shift early and translate insight into execution.
The upcoming pharmaverse webinar offers a structured opportunity to move beyond theory and engage directly with real-world applications. Led by industry experts actively working with pharmaverse, the session brings together perspectives from across the ecosystem, spanning implementation, standardization, and operationalization.
Participants will gain not just an introduction, but practical insights into how R-based workflows can be applied across the SDTM-to-ADaM pipeline, how key packages interact, and how organizations can begin their transition with clarity and confidence.
For teams looking to move from exploration to execution, this is a valuable starting point.
Join the session on May 07, 2026, and take a step toward building future-ready clinical programming capabilities.
Additional Resources
1) The One-Click Guide to Pharmaverse
Ross Farrugia
The blog introduces the Pharmaverse Examples site as a practical, end-to-end guide for running clinical workflows using R programming and open source data analytics tools. It highlights how users can launch a pre-configured environment instantly, removing setup barriers and enabling immediate hands-on exploration.
2) Your Gateway to Clinical Reporting with Open-Source Tools
Orla Doyle and Ross Farrugia
This blog introduces the pharmaverse examples site as a practical, end-to-end resource for clinical reporting using R. It showcases how multiple pharmaverse packages work together across the full pipeline, from raw data to SDTM, ADaM, and TLF outputs, using real, structured examples.
Learn more about our services and solutions by reaching out to us at